Rheumatology
Pediatric Rheumatology: General Concepts & Juvenile Idiopathic Arthritis (JIA)
- Most Common Pediatric Rheumatic Disease: ((QID004)): Juvenile Idiopathic Arthritis (JIA) is the most frequent pediatric rheumatic disorder, defined by chronic arthritis of unknown origin lasting $\ge$6 weeks with onset before 16 years of age.
- Oligoarticular JIA: ((((QID005)) · ((QID022)))): Most common subtype (40–50%), affecting $\le$4 joints (chiefly knees, ankles, elbows) in young girls (peak 2–4 years). Complication: High risk of asymptomatic chronic anterior uveitis, mandating baseline and serial slit-lamp examinations, strongly driven by ANA positivity. Initial Management: NSAIDs; if inadequate or for functional limits, use intra-articular triamcinolone hexacetonide ((QID008)). Recurrent synovitis after initial response indicates treatment failure requiring escalation to methotrexate, not repeat injections ((QID008)).
- Polyarticular JIA, RF-Positive: ((QID006)): Involves $\ge$5 joints with symmetrical small joint involvement (MCP, PIP) and morning stiffness. Closely mirrors adult rheumatoid arthritis, occurring predominantly in older girls (>8 years) with positive rheumatoid factor (RF) and anti-CCP antibodies.
- Systemic-Onset JIA (sJIA / Still's Disease): ((((QID007)) · ((QID012)) · ((QID026)) · ((QID033)))): Characterized by quotidian high-spiking fevers ($\ge$39°C) occurring daily/twice daily, an evanescent salmon-colored macular truncal rash that appears with fever peaks, hepatosplenomegaly, lymphadenopathy, and serositis (pericarditis). Labs: Markedly elevated ferritin, high ESR, but ANA and RF are characteristically negative. Pathophysiology: Autoinflammatory (IL-1 and IL-6 driven). Treatment: NSAIDs/steroids initially; refractory or steroid-dependent cases require biologic therapy targeting IL-1 (e.g., anakinra, canakinumab) or IL-6 (tocilizumab).
- Macrophage Activation Syndrome (MAS): ((((QID024)) · ((QID026)))): A life-threatening secondary HLH complication of sJIA. Buzzwords: Rapidly dropping platelet count, hyperferritinemia (often >10,000 ng/mL), hypofibrinogenemia, hypertriglyceridemia, transaminitis, and bone marrow hemophagocytosis. Clinical Hallmark: Paradoxically normal or low ESR (due to low fibrinogen consumption) amidst overwhelming systemic inflammation, coupled with high fever, mucosal bleeding, purpura, and multi-organ dysfunction.
- Enthesitis-Related Arthritis (ERA): ((QID023)): Predominantly affects older boys presenting with asymmetric lower-limb arthritis, enthesitis (tenderness at tendon insertions like the Achilles), and axial/lumbosacral spine involvement. Strongly associated with HLA-B27 positivity and ANA negativity.
- Psoriatic JIA: ((QID025)): Distinguished by arthritis plus dactylitis (sausage digits), nail pitting/onycholysis, or DIP joint involvement, often with a family history of psoriasis in a first-degree relative.
- Biologics & DMARDs in JIA: ((((QID002)) · ((QID003)) · ((QID009)) · ((QID010)) · ((QID011)) · ((QID013)))): - First-line DMARD: Methotrexate (MTX) (weekly, folate-supplemented). Toxicity: Megaloblastic macrocytic anemia and dose-dependent hepatotoxicity. - TNF Inhibitors: Etanercept, adalimumab, and golimumab are FDA-approved for polyarticular JIA after MTX failure. Infliximab lacks this specific FDA indication ((QID003)). - Mandatory Pre-Biologic Action: Screen for latent tuberculosis (TST or IGRA) before starting TNF inhibitors due to the risk of granuloma breakdown and TB reactivation ((QID013)). - JAK Inhibitors: Tofacitinib is the sole FDA-approved oral JAK inhibitor for pediatric polyarticular JIA (children $\ge$2 years and $\ge$10 kg) ((QID002)).
Juvenile Dermatomyositis (JDM)
- Diagnostic Criteria & Cutaneous Hallmarks: ((((QID016)) · ((QID018)) · ((QID034)))): Requires a characteristic rash plus at least three of the following: symmetric proximal muscle weakness, elevated muscle enzymes, characteristic EMG findings, or muscle biopsy showing perifascicular atrophy. - Rashes: Heliotrope rash (violaceous eyelid discoloration with periorbital edema; the most common cutaneous sign) and Gottron papules (violaceous papules over knuckles/extensor joints) ((QID016)).
- Muscle Enzymes & Markers: ((QID017)): Lactate dehydrogenase (LDH) is the most sensitive continuous marker for active muscle inflammation (often remaining elevated when CK fluctuates or is normal).
- Myositis-Specific Antibodies & Phenotypes: ((((QID014)) · ((QID015)) · ((QID019)))):
- Anti-MDA5:: Associated with rapidly progressive interstitial lung disease (ILD) (ground-glass opacities on HRCT), normal CK levels, and severe skin/palmar ulcerations with elevated ferritin.
- Anti-NXP2:: Predicts severe muscle weakness, prominent calcinosis cutis, and dangerous gastrointestinal vasculopathy/bleeding.
- Anti-Mi-2:: Classic rash pattern with a generally favorable prognosis and good response to therapy.
- Management: ((QID020)): Immediate combination therapy with high-dose oral prednisolone (2 mg/kg/day) plus a steroid-sparing agent like methotrexate, alongside aggressive sun protection and calcium/vitamin D supplementation.
Auto-inflammatory, Vasculitic, and Mimicking Conditions
- Reactive Arthritis (ReA): ((((QID027)) · ((QID028)) · ((QID029)))): Sterile inflammatory arthritis following enteric (Salmonella, Shigella, Yersinia, Campylobacter) or genitourinary (Chlamydia) infections. Features asymmetric lower-limb oligoarthritis, enthesitis, HLA-B27 positivity, and extra-articular manifestations (urethritis, circinate balanitis, keratoderma blennorrhagicum). Chronic cases (>6 months) unresponsive to NSAIDs/steroids require DMARDs (sulfasalazine or methotrexate) ((QID029)).
- Behçet's Disease: ((((QID031)) · ((QID032)))): Multisystem vasculitis defined by recurrent painful oral aphthous ulcers, genital ulcers, and ocular inflammation (classic anterior uveitis with hypopyon or posterior uveitis). Key associations: HLA-B51 positivity and a positive pathergy test (sterile pustule at needle-prick site). Neuro-Behçet's (presenting with cerebral venous sinus thrombosis/meningoencephalitis) mandates aggressive induction with high-dose IV corticosteroids plus cyclophosphamide ((QID032)).
- Growing Pains: ((QID021)): Benign intermittent, bilateral lower extremity (calf/thigh) pain occurring exclusively in the evening/night, resolving entirely by morning, with normal physical exam, normal growth, and completely normal inflammatory labs.
- Transient (Toxic) Synovitis of the Hip: ((QID030)): Most common cause of acute hip pain/limp in children aged 3–10 years, frequently following a viral URI. Characterized by a mild joint effusion, clear sterile aspirate, low-grade/afebrile status, and rapid self-resolution with rest and NSAIDs.
- (A) A–i, B–ii, C–iii, D–iv
- (B) A–ii, B–i, C–iii, D–iv
- (C) A–ii, B–iii, C–i, D–iv
- (D) A–iv, B–ii, C–iii, D–i
💡 Click to Reveal Answer & Nelson Rationale
Photosensitive malar rash that spares the nasolabial folds is suggestive of SLE. Diffuse facial rash is more indicative of JDM. A hyperkeratotic rash on the face or around the ears may represent discoid lupus. A palpable purpuric rash on the extensor surfaces of the lower extremities points to IgA vasculitis (Henoch–Schönlein purpura). Non-blanching erythematous papules on the palms are seen in vasculitis, SLE, and endocarditis.
- (A) Baricitinib
- (B) Ruxolitinib
- (C) Upadacitinib
- (D) Tofacitinib
💡 Click to Reveal Answer & Nelson Rationale
Many JAK inhibitors (JAKinibs) are currently available, including tofacitinib, baricitinib, ruxolitinib, and upadacitinib.Among these, only tofacitinib has FDA approval in pediatric rheumatic diseases. Tofacitinib is an oral JAK inhibitor that acts primarily on JAK1, JAK3, and to a lesser extent JAK2 enzymes.It has FDA approval for the treatment of polyarticular juvenile idiopathic arthritis (JIA) in children ≥2 years of age and ≥10 kg. **Dosing (BID oral):** 3.2 mg twice daily for 10–20 kg, 4 mg twice daily for 20–40 kg, 5 mg twice daily for >40 kg It is available as an oral solution (1 mg/mL) and oral tablets (5 mg). **Adverse effects:** Increased risk of serious infections and thrombosis (including pulmonary embolism, DVT, arterial thrombosis), Gastrointestinal perforations, Common side effects: upper respiratory infections, diarrhea, and headache.
- (A) Etanercept
- (B) Adalimumab
- (C) Golimumab
- (D) Infliximab
💡 Click to Reveal Answer & Nelson Rationale
Among TNF antagonists used in pediatric rheumatology, three agents have FDA approval for the treatment of children with moderate to severe polyarticular juvenile idiopathic arthritis (JIA) — etanercept, adalimumab, and golimumab. Infliximab, a chimeric mouse-human monoclonal antibody, was evaluated in a randomized controlled trial (RCT) for use in JIA but did not achieve study endpoints, and therefore does not have FDA approval for this indication.However, infliximab is FDA-approved for pediatric inflammatory bowel disease and is used off-label in polyarticular JIA, uveitis, Behçet syndrome, and sarcoidosis. Certolizumab pegol, a pegylated humanized anti-TNF antibody, is approved by the FDA for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis in adults and is currently under pediatric trials for polyarticular JIA. Three-fourths of children with active polyarticular JIA that fail to respond to methotrexate (MTX) show a good clinical response to etanercept after 3 months of therapy.Adalimumab is a fully human anti-TNF monoclonal antibody used alone or with MTX.Golimumab is a human monoclonal antibody that binds both soluble and transmembrane TNF, and has FDA approval for use in polyarticular JIA. Adverse effects:Injection-site reactions are the most common and generally decrease with time. TNF blockade increases the risk of serious systemic infections, including sepsis, reactivation of latent tuberculosis (TB), and invasive fungal infections in endemic regions.
- (A) Juvenile Dermatomyositis
- (B) Systemic Lupus Erythematosus
- (C) Juvenile Idiopathic Arthritis
- (D) Henoch–Schönlein Purpura
💡 Click to Reveal Answer & Nelson Rationale
Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children.It represents a heterogeneous group of autoimmune disorders characterized by chronic arthritis of unknown origin, persisting for ≥6 weeks, and presenting before 16 years of age. JIA is classified into several subtypes, including oligoarticular, polyarticular, systemic-onset, psoriatic, and enthesitis-related arthritis, among others.Early recognition and treatment are critical to prevent joint damage, growth abnormalities, and functional disability.
- (A) Oligoarthritis JIA
- (B) Polyarthritis (Rheumatoid factor negative) JIA
- (C) Polyarthritis (Rheumatoid factor positive) JIA
- (D) Systemic JIA
💡 Click to Reveal Answer & Nelson Rationale
Oligoarthritis is the most common subtype of juvenile idiopathic arthritis (JIA), accounting for 40–50% of all cases. It is characterized by arthritis involving four or fewer joints during the first six months of disease. The most commonly affected joints are the knees, ankles, and elbows. This subtype typically affects girls more than boys (3:1 ratio), with a peak age of onset between 2–4 years.In oligoarticular JIA, children are at increased risk of chronic anterior uveitis, particularly if antinuclear antibody (ANA) positive. Following oligoarthritis, polyarthritis accounts for about 25–30% of cases, and systemic JIA represents 5–15%.Polyarthritis (RF-negative) and (RF-positive) differ in their immunologic and prognostic profiles, with the RF-positive form resembling adult rheumatoid arthritis.
- (A) Oligoarticular JIA
- (B) Enthesitis-related arthritis
- (C) Polyarticular JIA, RF-positive
- (D) Systemic-onset JIA
💡 Click to Reveal Answer & Nelson Rationale
This child with morning stiffness, symmetrical involvement of small joints of the hands, and positive rheumatoid factor (RF) is characteristic of the polyarticular, RF-positive subtype of juvenile idiopathic arthritis (JIA). Polyarticular JIA is defined by involvement of five or more joints during the first six months of disease. The RF-positive form closely resembles adult rheumatoid arthritis (RA) in clinical and serologic features. **Key features include:** Symmetrical arthritis affecting small joints (e.g., MCP, PIP joints). Morning stiffness and gradual progression of joint deformities if untreated. Positive rheumatoid factor and often anti-CCP antibody positivity. Typically occurs in older girls (>8 years). This subtype often has a chronic, erosive course, and early initiation of DMARDs (e.g., methotrexate) is essential to prevent joint damage and disability.
- (A) Pericarditis
- (B) Salmon-pink evanescent rash
- (C) High risk of chronic anterior uveitis
- (D) Hepatosplenomegaly
💡 Click to Reveal Answer & Nelson Rationale
Systemic-onset JIA (sJIA) is a distinct subtype of juvenile idiopathic arthritis characterized by arthritis (which may be absent initially), quotidian fever, evanescent rash, and prominent visceral involvement including hepatosplenomegaly, lymphadenopathy, and serositis (such as pericarditis). The fever pattern is classically quotidian, with spiking temperatures ≥39°C (102.2°F) occurring daily or twice daily for at least 2 weeks, followed by rapid defervescence to normal or subnormal temperatures. The rash is described as evanescent, salmon-pink, macular, and nonpruritic, often accompanying the fever spikes. It is transient, with individual lesions lasting less than 1 hour, and typically distributed over the trunk and proximal extremities. Unlike oligoarticular JIA, systemic JIA carries a very low risk of chronic anterior uveitis, despite being an inflammatory subtype.
- (A) Repeat intra-articular steroid injection
- (B) Add methotrexate
- (C) Start systemic corticosteroids
- (D) Start etanercept
💡 Click to Reveal Answer & Nelson Rationale
Juvenile idiopathic arthritis (JIA) management follows a stepwise escalation strategy based on disease activity and treatment response. In oligoarticular JIA (≤4 joints), the treatment begins with nonsteroidal anti-inflammatory drugs (NSAIDs). If symptoms persist after 4–6 weeks or if there are functional limitations (e.g., contracture, leg-length discrepancy), intra-articular corticosteroid injections—most commonly triamcinolone hexacetonide—are used. Triamcinolone hexacetonide provides a long-lasting anti-inflammatory effect, but if recurrent synovitis occurs after an initial good response, it indicates persistent disease activity, and repeated intra-articular injections should be avoided. At this stage, the next step in therapy is the initiation of a disease-modifying antirheumatic drug (DMARD), most commonly methotrexate, administered weekly with folic acid supplementation. If methotrexate fails or is not tolerated, biologic DMARDs (bDMARDs) such as TNF inhibitors (etanercept, adalimumab) are considered. ![[5847696e_Treatment_1762234607.png]]
- (A) TNF inhibitors are first-line in systemic JIA with fever and rash
- (B) Tocilizumab acts by blocking IL-1 signaling
- (C) Etanercept is effective in polyarticular JIA after methotrexate failure
- (D) Rituximab is approved as first-line in polyarticular JIA
💡 Click to Reveal Answer & Nelson Rationale
In the management of juvenile idiopathic arthritis (JIA), biologic DMARDs (bDMARDs) are introduced when there is failure of methotrexate (MTX) monotherapy, presence of poor prognostic factors, or severe disease onset. **In polyarticular JIA (≥5 joints):** First-line: Methotrexate (weekly, low dose with folic acid), If MTX not tolerated: Leflunomide, If inadequate response: TNF inhibitors (e.g., etanercept, adalimumab, golimumab) are added. If resistant: Abatacept (T-cell costimulation modulator) or Tocilizumab (IL-6 inhibitor) are considered. Etanercept is a TNF inhibitor that has shown excellent efficacy in children with polyarticular JIA who do not respond to methotrexate. It is not used as initial therapy but is a key second-line biologic in MTX-refractory cases. In systemic JIA, TNF inhibitors are not effective for systemic features (fever and rash). When systemic symptoms dominate, treatment begins with systemic corticosteroids, followed by IL-1 inhibitors (Anakinra, Canakinumab) or IL-6 inhibitor (Tocilizumab), which typically induce a rapid and dramatic response.
- (A) Hemorrhagic cystitis
- (B) Pulmonary fibrosis
- (C) Macrocytic anemia and hepatotoxicity
- (D) Nephrotoxicity with hypomagnesemia
💡 Click to Reveal Answer & Nelson Rationale
Methotrexate (MTX) is a folate antagonist that inhibits dihydrofolate reductase, impairing DNA synthesis in rapidly dividing cells. It is a first-line disease-modifying antirheumatic drug (DMARD) used in polyarticular and extended oligoarticular JIA. **Adverse effects:** Hematologic: Megaloblastic (macrocytic) anemia, leukopenia, thrombocytopenia due to folate deficiency and bone marrow suppression. Hepatic: Hepatotoxicity is one of the most important dose-dependent toxicities; periodic liver function monitoring is recommended. Gastrointestinal: Nausea, vomiting, oral ulcers. Other: Fatigue, elevated transaminases, and, rarely, pulmonary toxicity. These toxicities are mitigated by weekly dosing and folic acid supplementation.
- (A) Hemorrhagic cystitis
- (B) Pulmonary fibrosis
- (C) Macrocytic anemia and hepatotoxicity
- (D) Nephrotoxicity with hypomagnesemia
💡 Click to Reveal Answer & Nelson Rationale
Methotrexate (MTX) is a folate antagonist that inhibits dihydrofolate reductase, interfering with DNA synthesis and repair in rapidly dividing cells.It is the first-line disease-modifying antirheumatic drug (DMARD) used in polyarticular and extended oligoarticular JIA. **The most characteristic adverse effects of methotrexate include:** Macrocytic (megaloblastic) anemia due to folate deficiency, Hepatotoxicity (elevated liver enzymes, risk of fibrosis with prolonged use), Bone marrow suppression (cytopenias) hese effects are minimized by weekly dosing and folic acid supplementation. Regular liver function and blood count monitoring are essential during therapy.
- (A) Etanercept
- (B) Anakinra
- (C) Rituximab
- (D) Abatacept
💡 Click to Reveal Answer & Nelson Rationale
This child has systemic-onset juvenile idiopathic arthritis (sJIA), which presents with quotidian fever, evanescent salmon-colored rash, arthritis, hepatosplenomegaly, and elevated ferritin levels. Initial therapy for sJIA includes NSAIDs and systemic corticosteroids. When the disease remains steroid-dependent or inadequately controlled, the next step is to start biologic DMARDs (bDMARDs) targeting key inflammatory cytokines such as IL-1 or IL-6. Anakinra, an IL-1 receptor antagonist, is the preferred biologic in such cases, especially when systemic features (fever and rash) dominate the clinical picture.Canakinumab (another IL-1 inhibitor) or Tocilizumab (IL-6 receptor blocker) are alternative biologics with proven efficacy in refractory or corticosteroid-dependent systemic JIA. TNF inhibitors (e.g., etanercept, adalimumab) are less effective for systemic symptoms and are used primarily in polyarticular JIA.
- (A) Baseline ANA and RF titers
- (B) Bone marrow aspiration
- (C) Screening for latent tuberculosis
- (D) Ophthalmology slit-lamp exam
💡 Click to Reveal Answer & Nelson Rationale
Before initiating biologic therapy, particularly TNF inhibitors (e.g., etanercept, adalimumab, infliximab), it is mandatory to screen for latent tuberculosis (TB) to prevent reactivation during treatment. TNF-α blockade impairs granuloma formation and immune containment of Mycobacterium tuberculosis, increasing the risk of reactivation of latent infection. Therefore: Tuberculin skin test (TST) or interferon-γ release assay (IGRA) must be performed before therapy. If positive, prophylactic anti-tubercular therapy should be started and completed (as per guidelines) before initiating the biologic. TNF inhibitors should not be used in patients with chronic, recurrent, or active infections. Other infection screenings (for hepatitis B, hepatitis C, HIV) may also be performed depending on regional protocols. Ophthalmology slit-lamp screening is essential in ANA-positive oligoarticular JIA to monitor for chronic anterior uveitis but is not mandatory before biologic initiation.
- (A) Anti-Mi-2
- (B) Anti-MDA5
- (C) Anti-NXP2
- (D) Anti-TIF1-γ
💡 Click to Reveal Answer & Nelson Rationale
Anti-MDA5 (melanoma differentiation-associated gene 5) antibody is strongly associated with juvenile dermatomyositis (JDM) presenting with rapidly progressive interstitial lung disease (ILD), normal or mildly elevated CK, ulcerative skin lesions, and markedly elevated ferritin levels. These patients often have clinically amyopathic dermatomyositis (CADM) with minimal muscle involvement but severe pulmonary disease. The presence of anti-MDA5 antibody indicates poor prognosis and a higher risk of mortality due to ILD. **Key associations of anti-MDA5 antibody:** Rapidly progressive ILD (ground-glass opacities on HRCT), Normal CK despite active disease, Skin ulcerations, palmar papules, Elevated ferritin (marker of inflammation/macrophage activation), Poor response to standard therapy
- (A) Anti-TIF1-γ
- (B) Anti-NXP2
- (C) Anti-MDA5
- (D) Anti-SAE
💡 Click to Reveal Answer & Nelson Rationale
Anti-NXP2 antibody (nuclear matrix protein 2) is associated with severe vasculopathic forms of juvenile dermatomyositis (JDM).Children with this antibody are at higher risk for gastrointestinal vasculopathy, leading to ulceration, bleeding, or perforation, and for calcinosis cutis due to chronic inflammation and vascular injury. **These patients often exhibit:** Severe muscle involvement with edema and weakness, Calcinosis as a chronic sequela, Vasculopathic GI complications including hemorrhage, ischemia, or perforation, Poorer long-term prognosis due to tissue damage **Mechanism:** Anti-NXP2 antibodies are directed against a nuclear matrix protein involved in chromatin regulation. Their presence correlates with endothelial injury and microvascular dysfunction, explaining the vasculopathic manifestations seen in JDM.
- (A) Gottron papules
- (B) Heliotrope rash
- (C) Photosensitivity rash
- (D) Livedo reticularis
💡 Click to Reveal Answer & Nelson Rationale
Heliotrope rash is the most common cutaneous manifestation of juvenile dermatomyositis (JDM), seen in 66–95% of affected children.It presents as violaceous to dusky erythema involving the upper eyelids, often accompanied by periorbital edema, giving a characteristic “heliotrope” discoloration. It is considered the hallmark skin lesion of dermatomyositis and often precedes or coincides with muscle weakness. **Other common cutaneous features of JDM include:** Gottron papules: Violaceous papules or plaques over bony prominences such as knuckles, elbows, and knees. Gottron sign: Macular erythema over extensor surfaces of joints. Photosensitive rash: Over sun-exposed areas such as the face and upper chest (shawl sign). Nailfold capillary changes: Dilated capillaries and periungual telangiectasias.
- (A) CK
- (B) LDH
- (C) Aldolase
- (D) AST
💡 Click to Reveal Answer & Nelson Rationale
In juvenile dermatomyositis (JDM), several muscle-derived enzymes are elevated due to myositis and muscle fiber damage, including: Creatine kinase (CK), Aldolase, Aspartate transaminase (AST), Alanine transaminase (ALT), Lactate dehydrogenase (LDH) Among these, LDH is considered the most sensitive enzyme for detecting ongoing muscle inflammation because it remains elevated even when CK levels are normal. **Key points:** CK levels may fluctuate and can be normal in active disease. ALT and AST elevations often accompany early muscle inflammation. LDH is therefore a useful and reliable marker for disease monitoring, especially during treatment response or relapse.
- (A) Diagnosis of dermatomyositis requires the presence of a characteristic rash and at least two signs of muscle inflammation and weakness
- (B) The peak age of onset is 7 years
- (C) Rash develops as the first symptom in 50% of patients and appears concomitant with weakness only 25% of the time
- (D) Anti-TIF-1-γ antibodies are associated with photosensitive rashes
💡 Click to Reveal Answer & Nelson Rationale
This statement is incorrect because the diagnostic criteria for dermatomyositis require a characteristic rash plus at least three (not two) signs of muscle inflammation and weakness.The accepted diagnostic components include: **Characteristic Rash:** Heliotrope rash (violaceous discoloration of eyelids with periorbital edema), Gottron papules (erythematous or violaceous papules over MCP and IP joints) Plus any three of the following: Symmetric proximal muscle weakness (especially in shoulder and pelvic girdle muscles), Elevation of muscle enzymes: Creatine kinase (CK), Aspartate transaminase (AST), Lactate dehydrogenase (LDH), Aldolase, Electromyographic abnormalities: Short, small polyphasic motor unit potentials, Fibrillations, positive sharp waves, insertional irritability, Muscle biopsy findings: Necrosis, regeneration, inflammation, and perifascicular atrophy Thus, a diagnosis of dermatomyositis requires rash + three of the above four features, not two.This distinction is important to differentiate JDM from other inflammatory or autoimmune myopathies.
- (A) Muscle biopsy
- (B) EMG
- (C) Myositis-specific antibody testing
- (D) Skin biopsy
💡 Click to Reveal Answer & Nelson Rationale
In a child presenting with classical clinical features of juvenile dermatomyositis (JDM) — such as heliotrope rash, Gottron papules, and proximal muscle weakness — and with MRI showing diffuse muscle edema, the diagnosis of myositis is already confirmed. Although CK may be normal, it does not exclude active muscle inflammation, as enzyme levels can vary across individuals. In this scenario, the next best step is to perform myositis-specific antibody (MSA) testing, which helps in: Subtyping the disease (e.g., anti-Mi-2, anti-MDA5, anti-TIF1-γ, anti-NXP2). Predicting clinical phenotype, complications, and prognosis. Anti-Mi-2: Classic rash, good prognosis. Anti-MDA5: Normal CK, ulcerative lesions, ILD. Anti-NXP2: Severe myopathy, calcinosis, GI vasculopathy. Anti-TIF1-γ: Photosensitive rash, lipodystrophy (no malignancy in children). Thus, antibody typing adds significant value to guide treatment intensity and follow-up planning, particularly when noninvasive modalities (MRI, labs) already confirm inflammation.
- (A) Oral prednisolone 2 mg/kg/day + methotrexate
- (B) IVIG monotherapy
- (C) Hydroxychloroquine alone
- (D) Wait for biopsy confirmation before treatment
💡 Click to Reveal Answer & Nelson Rationale
The child fulfills diagnostic criteria for classic juvenile dermatomyositis (JDM) — characteristic rash (heliotrope + Gottron papules), symmetric proximal muscle weakness, elevated CK, and MRI-confirmed myositis.The diagnosis is established; therefore, treatment should begin immediately to prevent muscle damage, contractures, and calcinosis. Early combination therapy with oral corticosteroids (Prednisolone 2 mg/kg/day) and methotrexate significantly improves outcomes and reduces long-term complications.Methotrexate serves as a steroid-sparing agent, minimizing side effects of prolonged corticosteroid therapy. **Adjunct measures:** Vitamin D and calcium supplementation to prevent steroid-induced bone effects. Sun protection: Daily use of high-SPF sunscreen to prevent rash exacerbation. Physical therapy to preserve muscle strength and prevent contractures. Nutritional support: NG or gastrostomy feeding in cases of pharyngeal weakness; bowel rest if GI vasculitis develops.
- (A) Amplified pain syndrome
- (B) Patellofemoral syndrome
- (C) Growing pains
- (D) Benign hypermobility syndrome
💡 Click to Reveal Answer & Nelson Rationale
![[1174d60c_Untitled_design__24__1761389157.png]]
- (A) Pericarditis
- (B) Renal failure
- (C) Uveitis
- (D) All of the above
💡 Click to Reveal Answer & Nelson Rationale
The above case is suggestive of Juvenile Idiopathic Arthritis (JIA). The presence of positive Antinuclear Antibody (ANA) confers an increased risk for asymptomatic anterior uveitis, requiring periodic slit-lamp examination for early detection. ANA positivity in JIA is associated with:→ Younger age at disease onset→ Female predominance→ Asymmetric arthritis→ Fewer joints involved over time
- (A) Polyarticular RF-negative JIA
- (B) Enthesitis-related arthritis (ERA)
- (C) Psoriatic arthritis
- (D) Systemic-onset JIA
💡 Click to Reveal Answer & Nelson Rationale
Classic features of ERA include enthesitis, axial involvement, HLA-B27 positivity, and older age of onset, typically in boys.
- (A) Macrophage activation syndrome (MAS)
- (B) Hematologic malignancy
- (C) Septic shock
- (D) Drug-induced pancytopenia
💡 Click to Reveal Answer & Nelson Rationale
MAS is a life-threatening complication of systemic-onset JIA, characterized by: Cytopenias (↓ WBC, ↓ platelets), Very high ferritin levels, Liver dysfunction, Organomegaly (hepatosplenomegaly), It is also known as secondary hemophagocytic lymphohistiocytosis (HLH)., Pathophysiology: Overactivation of macrophages and T lymphocytes → uncontrolled cytokine release → tissue damage., Clinical features:→ High spiking fevers→ Lymphadenopathy→ Hepatosplenomegaly→ Encephalopathy→ Purpura and mucosal bleeding, Laboratory findings: Thrombocytopenia, leukopenia Elevated liver enzymes, LDH, triglycerides, ferritin, Prolonged PT and aPTT, Low ESR due to hypofibrinogenemia (helps distinguish MAS from sJIA flare)
- (A) ANA positivity
- (B) Enthesitis
- (C) Dactylitis and nail pitting
- (D) High-grade fever and rash
💡 Click to Reveal Answer & Nelson Rationale
These are hallmark features of psoriatic arthritis, a subtype of Juvenile Idiopathic Arthritis (JIA). Diagnosis is made when a child has arthritis and psoriasis, or arthritis and at least two of the following: Dactylitis (sausage-like swelling of digits), Nail pitting or onycholysis, Psoriasis in a first-degree relative, The distinguishing features of psoriatic arthritis include:, Involvement of DIP joints, Asymmetric joint involvement, Nail pitting, Dactylitis (due to tenosynovitis and soft tissue swelling), Family history of psoriasis
- (A) Systemic JIA
- (B) Macrophage activation syndrome (MAS) secondary to systemic JIA
- (C) Acute lymphoblastic leukemia
- (D) Severe bacterial sepsis with DIC
💡 Click to Reveal Answer & Nelson Rationale
The clinical picture of daily high fevers, salmon-colored rash, arthritis, hepatosplenomegaly, and lymphadenopathy is classic for systemic-onset Juvenile Idiopathic Arthritis (sJIA). However, the laboratory findings indicate Macrophage Activation Syndrome (MAS) — a life-threatening hyperinflammatory complication of sJIA. Findings suggestive of MAS: Rapid fall in platelets (from 320,000 → 92,000/mm³), Very high ferritin (15,000 ng/mL), Hypofibrinogenemia, Hypertriglyceridemia, Elevated transaminases (AST, ALT), Bone marrow hemophagocytosis. Paradoxically low/normal ESR despite severe inflammation occurs due to consumption of fibrinogen and other acute-phase reactants — a key differentiating feature from active systemic JIA. Thus, the overall picture is diagnostic of MAS secondary to systemic JIA rather than isolated systemic JIA or an infectious/malignant process.
- (A) Postinfectious arthritis
- (B) Septic arthritis
- (C) Reactive arthritis
- (D) Enthesitis-related arthritis
💡 Click to Reveal Answer & Nelson Rationale
Points favoring Reactive Arthritis: Recent genitourinary tract infection preceding joint symptoms, Asymmetric oligoarticular arthritis predominantly involving the lower limbs, Elevated inflammatory markers (ESR, CRP) in early phase, Sterile synovial fluid with neutrophil predominance, HLA-B27 positivity, Etiology:Reactive arthritis typically follows infection with:, Enteric pathogens: Salmonella, Shigella flexneri, Yersinia enterocolitica, Campylobacter jejuni, Genitourinary pathogens: Chlamydia trachomatis (most common), Less common: E. coli, Clostridium difficile, Clinical features:, Arthritis: Asymmetric, oligoarticular, lower limb predilection (knees, ankles), Extra-articular features:, Urethritis / sterile pyuria, Circinate balanitis, ulcerative vulvitis, erythematous oral lesions, keratoderma blennorrhagica, Conjunctivitis or uveitis (classic triad of arthritis–urethritis–conjunctivitis is rare in children), Systemic features: Fever, malaise, fatigue, Laboratory findings: Raised ESR/CRP, sterile synovial fluid
- (A) Presence of neutrophil-predominant effusion
- (B) Monoarticular large joint involvement
- (C) Asymmetric arthritis with mucocutaneous lesions and axial symptoms
- (D) Elevated ESR and CRP
💡 Click to Reveal Answer & Nelson Rationale
Reactive arthritis is a sterile inflammatory arthritis that follows a gastrointestinal or genitourinary infection. The patient’s history of diarrhea 4 weeks earlier, sterile synovial fluid, asymmetric arthritis, mucocutaneous lesion (keratoderma blennorrhagica), and axial involvement (lumbosacral tenderness) are classical features. ![[8f97aeef_Untitled_design__29__1761627111.png]] Septic arthritis presents with purulent aspirate, positive bacterial culture, and requires urgent antibiotics. Reactive arthritis shows sterile inflammatory effusion and is often associated with HLA-B27 positivity and extra-articular features like balanitis, conjunctivitis, or keratoderma blennorrhagica.
- (A) Continue NSAIDs for 6 more months as most cases are self-limiting
- (B) Start DMARD therapy such as Sulfasalazine or Methotrexate
- (C) Begin long-term systemic corticosteroids for disease control
- (D) Escalate directly to biologic TNF-α inhibitor therapy
💡 Click to Reveal Answer & Nelson Rationale
The presentation suggests chronic Reactive Arthritis following enteric infection (bacillary dysentery). While most cases of reactive arthritis resolve within 6 months, persistence beyond this duration indicates chronic or refractory disease, requiring escalation of therapy. According to Nelson Textbook of Pediatrics, children with chronic reactive arthritis (>6 months) who do not respond to NSAIDs and intra-articular corticosteroids should be started on DMARDs such as: Sulfasalazine, Methotrexate
- (A) Post-streptococcal arthritis
- (B) Toxic synovitis (transient synovitis)
- (C) Septic arthritis
- (D) Nonsuppurative arthritis (post-viral/sterile inflammatory)
💡 Click to Reveal Answer & Nelson Rationale
Toxic synovitis (transient synovitis) is the most common cause of acute hip pain in children aged 3–10 years. It often follows a viral upper respiratory infection and presents as: Acute unilateral hip pain, Limp or refusal to bear weight, Mild joint effusion on ultrasound, Sterile, clear synovial fluid, Afebrile or low-grade fever, Child otherwise well-appearing, Investigations typically show: Mild elevation in ESR and CRP, Normal WBC count, Sterile aspirate, differentiating it from septic arthritis Course:, Benign and self-limiting; resolves within 7–10 days with rest and NSAIDs.
- (A) Systemic lupus erythematosus
- (B) Reactive arthritis
- (C) Behçet's disease
- (D) Juvenile idiopathic arthritis
💡 Click to Reveal Answer & Nelson Rationale
The triad of recurrent oral ulcers, genital ulcers, and ocular inflammation (uveitis) is classic for Behçet's disease, a chronic, relapsing, multisystem vasculitis. The disease is more prevalent in individuals from the Middle East, Mediterranean, and East Asia. HLA-B51 positivity and a positive pathergy test (development of a sterile pustule at the site of skin injury) further support the diagnosis. Ocular involvement, particularly anterior uveitis with hypopyon, can lead to visual impairment if untreated. Other features may include skin lesions (erythema nodosum, papulopustular eruptions), arthritis, neurologic or vascular involvement.
- (A) High-dose corticosteroids + cyclophosphamide
- (B) Methotrexate monotherapy
- (C) Hydroxychloroquine
- (D) Aspirin + NSAID only
💡 Click to Reveal Answer & Nelson Rationale
This patient has Neuro-Behçet’s disease, a severe manifestation of Behçet’s disease involving the central nervous system. The presence of oral ulcers, erythema nodosum-like rash, posterior uveitis, and venous sinus thrombosis is diagnostic. Neuro-Behçet’s requires high-dose intravenous corticosteroids (methylprednisolone) followed by immunosuppressive therapy such as cyclophosphamide, azathioprine, or anti-TNF agents (infliximab) to prevent relapses and long-term neurologic deficits. Methotrexate alone is inadequate for CNS vasculitis.
- (A) Systemic lupus erythematosus
- (B) Juvenile dermatomyositis
- (C) Behçet's disease
- (D) Systemic-onset juvenile idiopathic arthritis (sJIA)
💡 Click to Reveal Answer & Nelson Rationale
Quotidian fever, evanescent salmon-colored rash, and arthritis with negative ANA and normal CK are classic for Systemic-onset Juvenile Idiopathic Arthritis (sJIA), previously known as Still’s disease. This subtype of JIA is characterized by daily high-spiking fevers, transient rash that correlates with fever spikes, arthritis, hepatosplenomegaly, and lymphadenopathy. Laboratory findings show very high ESR, marked hyperferritinemia, normal CK, and negative ANA.sJIA is prone to develop macrophage activation syndrome (MAS) — suggested by very high ferritin levels and systemic inflammation. Key distinguishing point:sJIA is the only subtype of JIA classified as an autoinflammatory disease, not autoimmune, and typically ANA negative.
- (A) Systemic lupus erythematosus
- (B) Juvenile idiopathic arthritis
- (C) Juvenile dermatomyositis
- (D) Behçet's disease
💡 Click to Reveal Answer & Nelson Rationale
Heliotrope rash, Gottron papules, proximal muscle weakness, markedly elevated CK, MRI evidence of myositis, and muscle biopsy showing perifascicular atrophy are diagnostic of Juvenile Dermatomyositis (JDM). Anti-Mi-2 antibody positivity supports the diagnosis and is associated with a good response to corticosteroids.JDM is a chronic inflammatory myopathy of childhood characterized by immune-mediated small vessel vasculopathy affecting skin and muscle.